While rigorous controlled trials of cancer risk management strategies are few in the hereditary breast/ovarian cancer field, there is increasing evidence for the use of specific cancer risk management interventions, such as preventing ovarian cancer and reducing the risk of breast cancer associated with BRCA1/2 pathogenic variants [3]. The gene discussed is BRCA1; the disease is ovarian carcinoma.